+

WO1997005873A3 - Utilisation de fluconazole pour inhiber la croissance de cancers - Google Patents

Utilisation de fluconazole pour inhiber la croissance de cancers Download PDF

Info

Publication number
WO1997005873A3
WO1997005873A3 PCT/US1996/012474 US9612474W WO9705873A3 WO 1997005873 A3 WO1997005873 A3 WO 1997005873A3 US 9612474 W US9612474 W US 9612474W WO 9705873 A3 WO9705873 A3 WO 9705873A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
difluorophenyl
triazol
propan
bis
Prior art date
Application number
PCT/US1996/012474
Other languages
English (en)
Other versions
WO1997005873A2 (fr
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Priority to BR9609966A priority Critical patent/BR9609966A/pt
Priority to SK141-98A priority patent/SK14198A3/sk
Priority to HU9903420A priority patent/HUP9903420A3/hu
Priority to MX9800998A priority patent/MX9800998A/es
Priority to JP9508494A priority patent/JPH11510187A/ja
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to PL96324904A priority patent/PL324904A1/xx
Priority to IL12309596A priority patent/IL123095A0/xx
Priority to NZ315184A priority patent/NZ315184A/xx
Priority to EP96926806A priority patent/EP0841921A2/fr
Priority to AU66833/96A priority patent/AU711966B2/en
Publication of WO1997005873A2 publication Critical patent/WO1997005873A2/fr
Publication of WO1997005873A3 publication Critical patent/WO1997005873A3/fr
Priority to NO980473A priority patent/NO980473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une composition pharmaceutique pour le traitement de cancers ou de tumeurs chez les mammifères contient du 2-(2,4-difluorophényl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol et ses dérivés. On peut utiliser un agent chimiothérapeutique en combinaison avec le 2-(2,4-difluorophényl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol et ses dérivés, ainsi que des agents de potentialisation. Le 2-(2,4-difluorophényl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol et ses dérivés peuvent également être utilisés pour traiter des infections virales, soit seul(s), soit en association avec d'autres agents antiviraux ou avec un agent de potentialisation.
PCT/US1996/012474 1995-08-04 1996-07-30 Utilisation de fluconazole pour inhiber la croissance de cancers WO1997005873A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU66833/96A AU711966B2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers
IL12309596A IL123095A0 (en) 1995-08-04 1996-07-30 Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
HU9903420A HUP9903420A3 (en) 1995-08-04 1996-07-30 Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections
MX9800998A MX9800998A (es) 1995-08-04 1996-07-30 Uso de fluconazol para inhibir el crecimiento de canceres.
JP9508494A JPH11510187A (ja) 1995-08-04 1996-07-30 癌の成長を阻害するためのフルコナゾールの使用
BR9609966A BR9609966A (pt) 1995-08-04 1996-07-30 Uso de fluconazol para a inibição do desenvolvimento de cânceres
PL96324904A PL324904A1 (en) 1995-08-04 1996-07-30 Application of fluconazole in carcinoma development inhibition
SK141-98A SK14198A3 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers
NZ315184A NZ315184A (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers and viral infections
EP96926806A EP0841921A2 (fr) 1995-08-04 1996-07-30 Utilisation de fluconazole pour inhiber la croissance de cancers
NO980473A NO980473L (no) 1995-08-04 1998-02-03 Anvendelse av flukonazol for å inhibere cancervekst

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US60/001,889 1995-08-04
US08/674,180 1996-07-16
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections

Publications (2)

Publication Number Publication Date
WO1997005873A2 WO1997005873A2 (fr) 1997-02-20
WO1997005873A3 true WO1997005873A3 (fr) 1997-03-27

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012474 WO1997005873A2 (fr) 1995-08-04 1996-07-30 Utilisation de fluconazole pour inhiber la croissance de cancers

Country Status (18)

Country Link
EP (1) EP0841921A2 (fr)
JP (1) JPH11510187A (fr)
KR (1) KR19990036138A (fr)
CN (1) CN1195288A (fr)
AR (1) AR003175A1 (fr)
AU (1) AU711966B2 (fr)
BR (1) BR9609966A (fr)
CA (1) CA2229024A1 (fr)
CZ (1) CZ33798A3 (fr)
HU (1) HUP9903420A3 (fr)
IL (1) IL123095A0 (fr)
MX (1) MX9800998A (fr)
NO (1) NO980473L (fr)
NZ (2) NZ503921A (fr)
PL (1) PL324904A1 (fr)
SK (1) SK14198A3 (fr)
TR (2) TR199800270T1 (fr)
WO (1) WO1997005873A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906091B2 (en) 1999-08-13 2005-06-14 Uaf Technologies And Research, Llc Method of cancer treatment
US6916836B2 (en) 2000-09-26 2005-07-12 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections
US6984654B2 (en) 1997-05-16 2006-01-10 Uaf Technologies And Research, Llc Cancer treatments and pharmaceutical compositions therefor

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (fr) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto Unite motrice susceptible d'etre accouplee a une enceinte roulante et vehicule resultant
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
RU2201230C1 (ru) * 2001-12-24 2003-03-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство флузол, обладающее противогрибковым действием
EP1895012A1 (fr) * 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Méthode de l'induction de l'apoptose de cellules tumorales par l'augmentation du niveau d'oxyde d'azote
WO2008073961A2 (fr) * 2006-12-12 2008-06-19 Emory University Composés et procédés de modulation de la mise ai silence d'un polynucléotide d'intérêt
WO2019185521A1 (fr) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Inhibiteur de biosynthèse d'ergostérol et infection par le virus de la grippe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A2 (fr) * 1985-03-29 1986-10-08 Pfizer Inc. Tioconazole et composés apparentés pour la prévention des maladies transmises sexuellement et pour le contrôle des herpès
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
WO1996040120A1 (fr) * 1995-06-07 1996-12-19 The Procter & Gamble Company Utilisation de bis-1,2,4-triazoles dans la fabrication d'un medicament de traitement de cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A2 (fr) * 1985-03-29 1986-10-08 Pfizer Inc. Tioconazole et composés apparentés pour la prévention des maladies transmises sexuellement et pour le contrôle des herpès
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
WO1996040120A1 (fr) * 1995-06-07 1996-12-19 The Procter & Gamble Company Utilisation de bis-1,2,4-triazoles dans la fabrication d'un medicament de traitement de cancers

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984654B2 (en) 1997-05-16 2006-01-10 Uaf Technologies And Research, Llc Cancer treatments and pharmaceutical compositions therefor
US6906091B2 (en) 1999-08-13 2005-06-14 Uaf Technologies And Research, Llc Method of cancer treatment
US6916836B2 (en) 2000-09-26 2005-07-12 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections

Also Published As

Publication number Publication date
HUP9903420A3 (en) 2001-12-28
JPH11510187A (ja) 1999-09-07
CN1195288A (zh) 1998-10-07
AR003175A1 (es) 1998-07-08
PL324904A1 (en) 1998-06-22
NZ315184A (en) 2000-05-26
TR199800270T1 (xx) 1998-05-21
HUP9903420A2 (hu) 2000-03-28
SK14198A3 (en) 1999-03-12
WO1997005873A2 (fr) 1997-02-20
CZ33798A3 (cs) 1998-06-17
BR9609966A (pt) 1999-02-02
EP0841921A2 (fr) 1998-05-20
NZ503921A (en) 2002-03-01
IL123095A0 (en) 1998-09-24
NO980473L (no) 1998-04-03
MX9800998A (es) 1998-04-30
AU6683396A (en) 1997-03-05
NO980473D0 (no) 1998-02-03
AU711966B2 (en) 1999-10-28
CA2229024A1 (fr) 1997-02-20
TR199801739T2 (xx) 1998-12-21
KR19990036138A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
WO1997005873A3 (fr) Utilisation de fluconazole pour inhiber la croissance de cancers
WO1997005870A3 (fr) Emploi de griseofulvine pour inhiber la croissance des cancers
WO1997005872A3 (fr) Emploi de derives de 1h-1,2,4-triazole pour inhiber la croissance de cancers
CA2255951A1 (fr) 3,5-diphenyl-1,2,4-triazoles substitues et leur utilisation comme chelateurs de metaux pharmaceutiques
CA2217952A1 (fr) Composition pharmaceutique contenant du benzimidazole pour inhiber le developpement des cancers
CA2179008A1 (fr) Derives de 5-(2-imidazolinylamino)benzimidazole, leur preparation et leur utilisation en tant qu'agonistes de l'adrenocepteur alpha-2
AU2777089A (en) Substituted pyrrole, pyrazole and triazole angiotensin 11 antagonists
IL131900A0 (en) Fungicide active substance combinations
CA2338220A1 (fr) Imidazoles substitues a activite inhibitrice de la cytokine
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
PL322732A1 (en) Pharmaceutic agent containing n-chlorophenyl carbaminates and n-chlorophenyl thiocarbaminates for inhibiting development of viruses and carcinoma
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
NZ514558A (en) Viral treatment
GB2278115B (en) 2-(2-Hydroxyphenyl)-1,3-pyrimidine derivatives and their use as stabilizers for coating compositions
AU5491194A (en) Cytotoxic and antiviral compound
YU46302A (sh) Supstituisani piroli
IE800109L (en) Spiro-quinolylhydantoins
MY121813A (en) Nucleosides
AU4132693A (en) Substituted 1,2,4-triazine-3,5-dione derivative and anticoccidial drug composition containing the same as active component
EP0178682A3 (fr) 1,3-Bis(1H-1,2,4-triazol-1-yl)-2-fluoro-2-(2,4-difluorophényl)propane, composition fongicide le contenant et leurs procédés de préparation
AU4373785A (en) Dibenzyl-imidazole derivatives
MX9709712A (es) Uso de derivados de 1,2,4-triazol para la manufactura de un medicamento para el tratamiento de canceres.
MX9709530A (es) Uso de bis-1,2.4-triazoles para la manufactura de un medicamento para el tratamiento de canceres.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196682.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 14198

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2229024

Country of ref document: CA

Ref document number: 2229024

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980700806

Country of ref document: KR

Ref document number: 315184

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 508494

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-337

Country of ref document: CZ

Ref document number: 1998/00270

Country of ref document: TR

Ref document number: 1199800112

Country of ref document: VN

Ref document number: PA/a/1998/000998

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996926806

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996926806

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-337

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1998/01739

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1019980700806

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 2000702959

Country of ref document: KR

Kind code of ref document: A

WWR Wipo information: refused in national office

Ref document number: 1019980700806

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996926806

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-337

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载